Written by: Sean Brady Edited by: Esther Melamed Introduction The presence and quantity of pathogen-specific antibodies (such as SARS-CoV-2) can be an indicator of prior exposure to disease as well as an indicator of how well someone may be able to respond to that pathogen if they encounter it again. In a recent research letter in JAMA by Zoé L. E. van Kempen et al, a group of researchers analyzed SARS-CoV-2 antibodies in a large cohort of patients with multiple sclerosis (MS). This analysis enabled the authors to investigate the prevalence of asymptomatic cases as well as the antibody …
Neurological Tip of the Iceberg
Written by: Zohair Ahmed Edited by: Esther Melamed Since the start of the COVID-19 pandemic one year ago, COVID-19 research has become arguably one of the hottest topics in the history of research. One of the key emerging research areas at this time is the effect of the coronavirus, SARS-CoV-2, on individuals with “Post-Acute Sequelae of SARS-CoV-2 Infection” (PASC). PASC can present with varied symptoms but appears to affect different body organs. Emerging evidence on neurologic manifestations of PASC points to a spectrum of neurologic dysfunction in patients, ranging from mild …
Neurological and Psychiatric Sequelae at 6-Months Post-COVID-19
Written by: Sam Bazzi Edited by: Esther Melamed Neurological and psychiatric symptoms have been established as a common symptom and sequelae of COVID-19, but our understanding of how long neurological and psychiatric problems persist after infection is limited. A recent report from Taquet et al., published in The Lancet, describes a retrospective cohort study that analyzed the electronic health records of over 200,000 COVID-19 patients in order to track neurological and psychiatric health outcomes at 6 months post-infection. The authors enrolled patients from three cohorts: patients …